A Texas woman alleging she was harmed because of outdated warnings on generic metoclopramide may proceed with her suit alleging the manufacturers failed to incorporate changes approved for the branded reflux drug Reglan, the U.S. District Court for the Southern District of Texas held March 7 (Garza v. Wyeth LLC, S.D. Texas, No. 12-00198).
Maria Luisa Garza and Oscar Garza Sr. allege she developed abnormal muscle movements caused by long-term metoclopramide use. The plaintiffs contend Teva Pharmaceuticals USA Inc., Watson Laboratories, and Watson Pharma failed to conform their labels after the Food and Drug Administration approved changes to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.